Heart Disease :: Coronary Artery Disease ARISE Clinical Trial data announced

AstraZeneca announced that its collaboration partner AtheroGenics, Inc. (Nasdaq: AGIX) revealed first results from the ARISE (Aggressive Reduction of Inflammation Stops Events) phase III clinical outcomes trial which studied AGI-1067, an investigational anti-atherosclerotic agent with antioxidant and anti-inflammatory effects, in patients with coronary artery disease (CAD).

Fruits :: Americans not eating enough fruits and vegetables

“Eat your vegetables” has been heard at the dinner tables of America for a long time. Has the message gotten through? Since 1990 the Dietary Guidelines for Americans has recommended consuming at least two servings of fruits and three servings of vegetables daily. However, two studies published in the April issue of the American Journal of Preventive Medicine clearly show that Americans are not meeting the mark.

Life Span :: Life span gap between US blacks and whites narrows

Reductions in the death rate from homicide, HIV disease, unintentional injuries – and among women, heart disease – have contributed to narrowing the life expectancy gap between blacks and whites in the United States, although substantial inequalities and challenges remain, according to a study in the March 21 issue of JAMA.

Obesity :: Obesity high among Baltimore’s homeless

A small but telling study from the Johns Hopkins Children?s Center reveals an ominous trend: more than expected, obesity shadows Baltimore?s homeless children and their caregivers, putting them at high risk for heart disease, stroke and type 2 diabetes, among other conditions.

Stroke :: Tracing broken wiring in stroke patients

Researchers have used a technique to trace the functional disruption in brain circuitry that causes stroke patients to show a lack of awareness or response to the side of the body opposite to the side of the stroke lesion in the brain. The researchers said their findings shed new light on the neurological details of this “spatial neglect.”

Heart Failure :: Cardiovascular protective benefits of carvedilol in heart failure patients

Patients with heart failure who received the heart medication carvedilol suffered fewer heart attacks and strokes and were less likely to die of these and other vascular events than patients prescribed another beta blocker, metoprolol tartrate, according to a retrospective analysis of COMET (the Carvedilol or Metoprolol European Trial) published in the March 6th issue of The Journal of the American College of Cardiology.

Dr. Anil Singhal Homeopathic Doctor | Dr. Anil Singhal's Blog | Manan - My Memoir by Dr. Anil Singhal | Boger's Legacy | Organon of Medicine | Health Newstrack